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Abstract
Background: The indications and strategies for treatment of patent ductus arteriosus (PDA) are controversial, and
the safety and long-term benefits of surgical PDA closure remain uncertain. The aim of this study was to compare
the lung function of very low birth weight (VLBW) infants after successful PDA treatment with a cyclooxygenase
inhibitor or secondary surgical ligation.
Methods: A total of 114 VLBW infants (birth weight < 1500 g), including 94 infants (82%) with a birth weight < 1000 g,
who received treatment for hemodynamically significant PDA (hsPDA), were examined at a median postmenstrual age
of 48 weeks. All infants were initially given pharmacological treatment, and 40 infants (35%) required PDA ligation.
Lung function testing (LFT) included tidal breathing measurements, measurement of respiratory mechanics assessed by
the occlusion test, whole-body plethysmography, SF6 multiple breath washout, forced expiratory flow (V’maxFRC) by the
rapid thoracoabdominal compression technique, exhaled NO (FeNO), and arterialized capillary blood gas analysis.
Results: On the day of the LFT, the 2 groups had similar postconceptional age and body weight. However, the PDA
ligation group was more immature at birth (p < 0.001) and had reduced respiratory compliance (p < 0.001), lower
V’maxFRC (p = 0.006), increased airway resistance (Raw) (p < 0.001), and impaired blood gases (p < 0.001). Multivariate
analysis showed that PDA surgery was an independent risk factor for increased Raw.
Conclusion: PDA ligation after failed pharmacological treatment is associated with impaired lung function as
compared to successful pharmacological closure in infants at a postmenstrual age of 48 weeks. However, only Raw was
independently affected by PDA ligation, while all other differences were merely explained by patient characteristics.
Keywords: Patent ductus arteriosus, Ligation, Lung function test, Body plethysmography, Tidal breathing, Respiratory
mechanics, Lung volume, VLBW infants
Background
A persistently patent ductus arteriosus (PDA) affects
about one-third of premature infants with very low birth
weight (VLBW) and two-thirds of those with extremely
low birth weight (ELBW). Left-to-right shunting through
the PDA impairs systemic perfusion, and pulmonary
overcirculation may lead to pulmonary edema, increased
duration and intensity of mechanical ventilation, im-
paired alveolar development, and ultimately bronchopul-
monary dysplasia (BPD) [1].
This provides the rationale for PDA treatment, although
there are different opinions regarding the indications and
treatment strategies based on consideration of the poten-
tial benefits and adverse effects [1, 2]. Pharmacological
treatment with a cyclooxygenase (COX) inhibitor such as
indomethacin or ibuprofen leads to PDA closure with a
similar efficacy reported for both drugs [1, 3]. When
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medical treatment is contraindicated or unsuccessful,
PDA ligation provides definitive closure. Although the
morbidity and mortality rates following PDA ligation are
generally low, previous studies have linked this procedure
with severe complications such as left ventricular and re-
spiratory compromise, pneumothorax, chylothorax, in-
creased risk of BPD, thoracic scoliosis, and neurosensory
impairment [4, 5]. However, it is unclear whether these
adverse outcomes are causally associated with surgery it-
self or merely reflect the more severe illness and/or longer
exposure to PDA-related circulatory effects in these pa-
tients [6]. Another potentially underestimated complica-
tion of PDA surgery is injury to the recurrent laryngeal
nerve. This condition may result in voicing disorders and
impediments to gas flow in the proximal airways with pos-
sible persistence of symptoms into adulthood [7].
The unfavorable short-term effects of PDA on pul-
monary mechanics, formation of pulmonary edema, and
higher ventilator dependence are well established. How-
ever, a direct role of PDA in the development of chronic
lung disease/BPD has not yet been proven unequivocally.
Several studies have assessed the short-term effects of
pharmacological or surgical PDA closure on pulmonary
function in animal models [8, 9] and in ventilated infants
[10–12]. We hypothesize that different treatment effects
can also be seen in VLBW infants by postnatal lung
function testing (LFT). To our knowledge, no previous
studies have compared LFT results of spontaneously
breathing infants after pharmacological PDA treatment
vs. secondary surgical closure during early infancy. The
aim of this study was to compare LFT results of infants
with PDA who achieved closure following successful




This retrospective study examined 114 VLBW infants
(birth weight < 1500 g) who had hemodynamically sig-
nificant PDA (hsPDA) and underwent LFT during early
infancy. All patients initially received pharmacological
treatment; this initial treatment failed in 40 patients,
who then underwent PDA ligation. We used the clinical
risk index for babies (CRIB) score to assess initial
neonatal risk of hospital mortality. This scoring system
considers birth weight, gestational age, maximum and
minimum fraction of inspired oxygen, maximum base
excess during the first 12 h of life, and presence of con-
genital malformations. Infants were assessed between
November 2004 and February 2014 at a median post-
menstrual age of 48 weeks. LFT is a part of our routine
follow-up care of infants after neonatal intensive care.
Infants with congenital heart disease, neuromuscular
disease, or thoracic wall deformities were excluded.
An hsPDA was defined by the following criteria: (i) re-
spiratory set-back with supplemental oxygen require-
ment of more than 30% and/or mechanical ventilation
and/or (ii) left atrium to aortic root ratio of at least 1.4
in the echocardiogram, (iii) ductal size (>1.5 mm) and
flow pattern, and/or (iv) decreased end-diastolic flow in
the anterior cerebral artery with a resistance index of at
least 0.85 based on cerebral ultrasound. Therapy was ini-
tiated according to a previously published algorithm
[13]. When the PDA persisted despite pharmacological
treatment and infants could not be weaned from mech-
anical ventilation, surgical closure with a vascular clip or
suture was performed via a posterolateral thoracotomy.
Enrolled infants were classified into two groups accord-
ing to treatment: (i) no PDA ligation (pharmacological
closure with intravenous indomethacin or intravenous or
oral ibuprofen, N = 74), and (ii) surgical closure by PDA
ligation (N = 40). All parents provided written informed
consent before LFT, and the Institutional Data Safety
Committee approved this study.
Lung function testing
LFT was performed in clinically stable children who had
no lower airway infections in the preceding 3 weeks.
The departmental protocol for LTF has previously been
published [14]. Briefly, prior to testing, body weight and
body length (crown to heel) were measured. At 15–
30 min before LFT, sleep was induced by oral adminis-
tration of chloral hydrate (50 mg∙kg−1). Sleeping infants
were measured while in a supine position, with the neck
supported by a neck roll in a neutral position. A compli-
ant silicon infant mask (size 1, 2 or 3 as appropriate;
Vital Signs Inc., Totowa, NJ, USA) was tightly placed
over the nose and mouth.
Tidal breathing parameters (tidal volume [VT], respira-
tory rate [RR], minute ventilation [V’E], peak tidal in-
spiratory flow [PTIF], peak tidal expiratory flow [PTEF],
and the ratio of time to peak tidal expiratory flow to ex-
piratory time [tptef/te]) were initially measured by the
deadspace free flow-through technique using custom-
made equipment as previously described [15]. This tech-
nique allows long-term measurements in preterm infants
because the face mask and flow sensor are continuously
and thoroughly rinsed by a constant background flow
which virtually eliminates dead space in the apparatus.
The flow-through technique also allows continuous
monitoring of mask leaks. After these initial measure-
ments, respiratory lung mechanics (respiratory com-
pliance [Crs] and respiratory resistance [Rrs]) were
measured by the occlusion technique using a balloon
shutter. These measurements were performed using the
MasterScreen™ BabyBody Plethysmograph (CareFusion,
Höchberg, Germany), which also provides measurements
of respiratory mechanics, whole-body plethysmography,
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and forced expiratory flow. Airway resistance (Raw) and
functional residual capacity (FRCpleth) were also measured
using the constant-volume baby body plethysmograph.
The maximal expiratory flow at functional residual
capacity (V’maxFRC) was measured using the rapid
thoraco-abdominal compression technique with the same
equipment according to international guidelines [16].
Finally a multiple breath washout (MBW) technique
was performed, with 4% sulfur hexafluoride (SF6) as a
tracer gas, using the EXHALYZER D (EcoMedics AG,
Duernten, Switzerland) to determine the lung volume in-
volved in gas exchange (FRCSF6) and the lung clearance
index (LCI) as a measure of ventilation inhomogeneity.
Use of the same equipment in combination with the
fast chemiluminescence NO-analyzer CLD 88 (EcoMedics
AG, Duernten, Switzerland) allowed measurement of
exhaled nitric oxide concentration (FeNO) and NO
production (V’NO).
All flow and volume values were related to the body
weight on the day of measurement to reduce the inter-
subject variability. V’maxFRC was also expressed in stand-
ard deviation scores (Z-scores) that were based on sex,
corrected age, and height-specific reference values of
healthy infants published by Hoo et al. [17] and adjusted
for the MasterScreen™ BabyBody by Lum et al. [18].
An arterialized capillary blood gas sample was taken at
the end of LFT and analyzed using an ABL800 FLEX
(Radiometer, Denmark). Heart rate and oxygen satur-
ation were monitored continuously by a pulse oximeter
(N-200; Nellcor, Hayward, California, USA) during the
LFT. Complete data were obtained from almost all of the
114 infants regarding patient characteristics, occlusion test
results, whole-body plethysmography, and blood gas ana-
lysis. The equipment for tidal breathing measurements
was not available in 7 (6%) cases due to unplanned main-
tenance work. The rapid thoraco-abdominal compression
technique for measurement of V’maxFRC (N = 95) and
the SF6 MBW for measurement of FRCSF6 and LCI
(N = 76) were added later in our lung function labora-
tory. The last added device (smallest number of measure-
ments) was the Analyzer CLD 88 for measurement of
FeNO (N = 45).
Statistical methods
Patient characteristics and lung function parameters are
given as rates or medians and interquartile ranges
(IQRs). Data of infants with and without PDA ligation
were compared by Fisher’s exact test, the Mann-Whitney
rank test, or the Kruskal-Wallis rank test as appropriate.
Spearman rank correlation was used to determine the cor-
relation of the time of ligation with lung function parame-
ters. A multivariate analysis of variance (MANCOVA) was
used to investigate the effect of patient characteristics at
birth and the day of measurements on various respiratory
parameters. Statistical analysis was performed using Stat-
graphics Centurion® software (Version 16.0, Statpoint Inc.,
Herndon, Virginia, USA) and MedCalc (Version 9.2.0.2;
MedCalc Software, Mariakerke, Belgium). A p-value less
than 0.05 was considered statistically significant.
Results
Subjects
Table 1 shows the characteristics of the 114 enrolled
VLBW infants who had PDA. Seventy-four (65%) infants
received pharmacological treatment alone, and 40 (35%)
infants received PDA ligation after failure of the initial
pharmacological treatment. Infants in the PDA ligation
group had a significantly lower gestational age (p < 0.01),
lower birth weight (p < 0.018), and a higher incidence and
a longer duration of mechanical ventilation (p < 0.001 for
both). Moreover, assessment of risk-adjusted mortality
(CRIB score) showed that infants in the PDA ligation
group had higher CRIB scores (p = 0.003). The proportion
of ELBW infants was the same in both groups (data not
shown). There were also no statistically significant differ-
ences between the groups with respect to gender, fetal
lung maturation, or surfactant treatment. Among the 40
(35%) infants treated with surgical ligation, the median
(IQR) age at the time of surgery was 19 days.
At the day of LFT, there were no statistically signifi-
cant differences between the groups regarding chrono-
logical and postmenstrual age, body weight, and body
length. The LFT was performed at a median (IQR) post-
menstrual age of 48.3 (45.3–51.6) weeks. None of the
enrolled infants required additional oxygen or any re-
spiratory support on the day of testing.
Lung function testing
Table 2 shows the LFT results of infants in the 2 groups.
Analysis of tidal breathing parameters indicated that the
PDA ligation group had a lower VT (p < 0.007) and a
trend for lower PTEF (p = 0.078). Comparison of forced
expiratory flow parameters indicated the ligation group
had significantly lower V’maxFRC (p = 0.019) and corre-
sponding z-score (p = 0.006). The respiratory mechanics
were significantly different between both patient groups.
Infants with PDA ligation had a significantly reduced
compliance, increased airway resistance (Fig. 1) (p < 0.001
for both), and showed a trend for greater respiratory
resistance (p = 0.076). Both patient groups had similar
FRCPleth, FRCSF6, and LCI as well as similar flow and
concentration of exhaled NO, however, the PDA
ligation group had significantly lower paO2 and higher
paCO2 (p < 0.001 for both).
Multivariate analysis of variance
We used multivariate analysis of variance (MANCOVA)
to investigate the impact of patient characteristics at
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birth and on the day of measurements as well as the du-
rations of mechanical ventilation and hsPDA on max-
imal expiratory flow at functional residual capacity
(V’maxFRC), respiratory compliance (Crs), and airway re-
sistance (Raw). The results indicate that the differences
of V’maxFRC and Crs between both patient groups mainly
depended on patient characteristics (p < 0.05 for both),
but Raw did not. Moreover, PDA ligation had a signifi-
cant effect on Raw (p < 0.001), but not V’maxFRC and Crs.
Discussion
There is an ongoing debate on the potential harms and
benefits of PDA treatment in neonates. An hsPDA is
thought to negatively affect pulmonary outcomes, how-
ever, the different treatment options for PDA (pharma-
cological, surgical, interventional) themselves exhibit
potential risks and unclear benefits [1, 2, 19]. Chen et al.
recently provided important data showing that preterm
infants who received conservative management for PDA
had a higher percentage of BPD than the infants without
PDA, but LFT results were comparable between these
two groups at discharge [20]. However, these authors did
not investigate the effects of specific pharmacological or
surgical PDA treatment on LFT. We herein retrospect-
ively analyzed LFT data of a large cohort of VLBW in-
fants at 48 postconceptional weeks after successful
pharmacological PDA treatment or PDA ligation sec-
ondary to failed pharmacological treatment.
Our data shows that infants who underwent PDA
ligation exhibited alterations in their lung function parame-
ters as compared to those who received successful pharma-
cological treatment. Specifically, the PDA ligation group
had reduced respiratory compliance, lower V’maxFRC, in-
creased airway resistance (Raw), tidal volume, forced expira-
tory flow, and impaired blood gases.
One major limitation of our study lies in the strong
differences between the two groups: At birth the infants
who received PDA ligation were more immature and
sicker (with significantly higher CRIB scores), and had a
longer duration of mechanical ventilation. These factors
are associated with higher failure rates of pharmaco-
logical intervention for PDA in infants [21]. This is a
common problem in the literature on PDA treatment,
and due to a lack of randomized trials encompassing a
non-treatment arm, researchers have to rely on retro-
spective analysis which impairs the possibility to estab-
lish causal relationships [1, 21]. In order to somewhat
circumvent this problem, we conducted a multivariate
analysis accounting for the differences in birth weight,
gestational age, and durations of hsPDA and mechanical
ventilation. This analysis showed that PDA ligation itself
was an independent risk factor for increased airway re-
sistance while all other parameters were not independ-
ently affected by PDA ligation.
After PDA ligation, we observed an increased airway
resistance indicating upper airway obstruction that was
Table 1 Characteristics of the 114 infants with PDA who were treated with and without PDA ligation
Without PDA ligation With PDA ligation p-value
N = 74 N = 40
Neonatal period
Male 29 (50%) 21 (53%) 0.171
Gestational age (weeks) 26 (25–28) 25 (24–26) <0.001
Birth weight (g) 835 (690–990) 744 (630–860) 0.018
Birth weight <1000 g 58 (78%) 36 (90%) 0.120
Prenatal steroidsa 55/72 (76%) 31/38 (82%) 0.531
Surfactant administrationa 66/72 (92%) 36/39 (92%) 0.906
Duration of hsPDA (days) 10.5 (7 – 23) 19 (16 – 26) <0.001
Mechanical ventilation >24 h 53 (72%) 40 (100%) <0.001
Duration of mechanical ventilation (days) 14 (5 – 26) 26.5 (14.5 – 33.5) <0.001
Duration of mechanical ventilation up to PDA closure (days) 6 (3 – 10) 12.5 (5.5 – 17.5) 0.003
CRIB scorea 5 (1–8) 9 (5–11) 0.003
At day of lung function testing
Age (days) 157 (140 – 176) 160.5 (137 – 186) 0.587
Postconceptional age (weeks) 48.3 (45.3 – 51.6) 48.0 (45.4 – 51.0) 0.622
Body weight (g) 4300 (3800 – 5100) 4422 (3795 – 5100) 0.478
Body length (cm) 54.5 (52.5 – 57.0) 55.3 (52.75 – 58.0) 0.448
Data represent median (interquartile range) or n (%), statistically significant p-values are printed in bold
aTotal number is reduced because some data of outpatients were incomplete
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independent of immaturity and postnatal development
including durations of hsPDA and mechanical ventila-
tion. Although patient characteristics influence the re-
duction of V’maxFRC and Crs, only PDA ligation seems
to increase Raw (Table 3). This increase is only weakly
reflected by Rrs, because Raw (measured by whole-body
plethysmography) primarily describes air conductivity of
the upper airways, whereas Rrs (measured by an airway
occlusion test) describes the resistive properties of the
whole respiratory system, including the resistance of
lung tissue. The increase of Raw and the expiratory flow
limitation during tidal breathing in infants who under-
went PDA ligation points to problems in their upper air-
ways. It is tempting to speculate that this proximal
airway obstruction was due to unilateral vocal fold par-
alysis (UVFP) following injury of the recurrent laryngeal
nerve. A recent meta-analysis indicated that UVFP oc-
curred in up to 40% of children after surgical PDA
closure [22]. In corroboration, adults with UVFP have
increased Raw and, accordingly decreased specific air-
way conductance [23]. Unfortunately, a laryngoscopic
Table 2 Lung function testing of infants treated with and without PDA ligation
N hsPDA successfully treated
with COX inhibitors
PDA ligation after unsuccessful
treatment with COX inhibitors
p-value
Tidal breathing
VT (mL/kg) 107 5.96 (5.27 – 6.39) 5.15 (4.35 – 6.10) 0.007
RR (1/min) 107 40.0 (36.0 – 47.0) 43.5 (36.0 – 47.0) 0.132
V’E (mL/min/kg) 107 234.2 (207.3 – 274.3) 221.6 (186.6 – 252.0) 0.137
PTIF (L/min/kg) 107 0.85 (0.77 – 1.0) 0.87 (0.71 – 0.98) 0.984
PTEF (L/min/kg) 107 0.77 (0.64 – 0.96) 0.71 (0.58 – 0.88) 0.078
tptef/te (%) 107 18.1 (14.1 – 24.5) 17.2 (15.4 – 23.3) 0.896
Forced expiratory flow
V’max FRC (mL/s) 95 42.0 (25.0 – 61.0) 31.0 (13.0 – 52.0) 0.019
Z-Score V’maxFRC 95 −1.82 (−2.48 – −1.07) −2.53 (−3.0 – −1.74) 0.006
Respiratory Mechanics
Crs (mL/kPa/kg) 114 9.6 (8.1 – 10.6) 7.2 (6.3 – 9.1) <0.001
Rrs (kPa/L/s) 114 6.6 (5.2 – 8.3) 7.5 (6.3 – 8.3) 0.076
Raw (kPa/L/s) 114 2.84 (1.70 – 4.19) 4.81 (3.64 – 6.14) <0.001
Lung volumes and lung clearing index
FRCPleth (mL/kg) 114 20.9 (18.8 – 24.2) 21.1 (18.0 – 23.9) 0.852
FRCSF6 (mL/kg) 76 19.7 (15.6 – 24.3) 22.4 (18.6 – 25.2) 0.168
LCI 76 6.0 (5.5 – 6.8) 6.0 (5.7 – 6.9) 0.601
Exhalation gas analysis
eNO (ppb) 45 9.0 (3.3 – 18.2) 7.9 (3.7 – 11.3) 0.851
V’NO (nL/s) 45 11.8 (3.8 – 26.4) 14.4 (7.3 – 26.4) 0.617
Blood gas analysis
paO2 (mmHg) 113 70.6 (60.7 – 80.7) 59.7 (50.8 – 70.9) <0.001
paCO2 (mmHg) 113 40.9 (38.1 – 44.3) 45.1 (42.0 – 52.2) <0.001
N: number of lung function tests, presented as median and (IQR), statistically significant p-values are printed in bold
Fig. 1 Airway resistance (Raw), measured by baby body
plethysmography, of infants treated with and without PDA ligation
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evaluation of vocal fold motility was only performed
in a small number of infants in the present study,
and this prevented statistical evaluation. In light of a
possible increased risk of UVFP, it seems prudent to
routinely perform laryngoscopic evaluation in VLBW
infants after PDA ligation. LFT is an additional tool
to identify infants with upper airway obstruction and
to quantify the severity of the airflow impediment. Of
note, LFT in infants is non-invasive, as opposed to
laryngotracheoscopy, and might help detect incipient
upper airway obstruction before the onset of clinical
symptoms such as stridor or dyspnea.
V’maxFRC (measured by the rapid thoracoabdominal
compression technique) describes small airway conduct-
ivity and is highly dependent on maturity. Previous stud-
ies showed that V’maxFRC was lower in preterm infants,
even in the absence of neonatal disease or therapy
[24, 25]. Of note, the differences in tidal breathing
parameters were smaller than in other LFT parame-
ters; the only difference was a reduced VT relative to
body weight in the PDA ligation group. There were
no significant differences in PTEF and respiratory
rate, probably due to the high inter-subject variability
of tidal breathing at this age [26–28] Also, the two
groups had no significant differences in lung volume
relative to body weight, lung clearance index, or in an
inflammatory marker (exhaled FeNO).
In general, data on LFT in infants after PDA treat-
ment, especially after ligation, is sparse. Only a few stud-
ies assessed the short-term effects of PDA ligation on
pulmonary function in ventilated patients, and the re-
sults were contradictory. Two early case series from the
late 1970s showed increased pulmonary compliance after
surgical PDA closure in ventilated preterm infants
[10, 11], and a more recent prospective study of 16
ventilated VLBW infants demonstrated improvements
of dynamic compliance (Cdyn), VT, and V’E after PDA
ligation, although Raw, mean airway pressure, and
peak inspiratory pressure remained unchanged [12].
In contrast, McCurnin et al. [8] investigated the effect of
PDA ligation in a premature baboon model and found no
significant differences in Cdyn, oxygenation index, or venti-
lation index (VI), but a trend towards higher Cdyn and
lower VI in ligated animals. The post mortem static lung
compliance was similar in both groups of baboons. An-
other study by the same group confirmed the modest ef-
fects of ligation on lung function parameters, but reported
no improvement in alveolar surface area [9].
Our data shows that, compared to infants after suc-
cessful pharmacological PDA treatment, patients after
PDA ligation exhibited an increase in upper airway re-
sistance and a decreased respiratory compliance at a
postconceptional age of 48 weeks. The increased upper
airway resistance seems to be associated with PDA sur-
gery itself. In contrast, all the other impairments in pul-
monary mechanics observed in ligated infants were due
to the patient characteristics, and, despite all the hetero-
geneity between groups, several LFT parameters showed
no significant differences. The differences in the LFT pa-
rameters were also reflected by blood gas analysis. We
used arterialized capillary rather than arterial blood gas
analysis because it is less invasive, easier to perform, and
shows a good correlation with arterial blood gas analysis
for most parameters.
There is an ongoing controversy regarding the indica-
tions and protocols for treatment of PDA [1, 2, 21, 29].
Herein, we provide data that might support an adverse
association between some LFT parameters and PDA
ligation. It is nonetheless unclear if this is a causal rela-
tionship or just an epiphenomenon due to the more se-
vere illness of infants who required surgery. A recent
study by Schena et al. found a higher incidence of BPD
in infants after PDA ligation [30], but their multivariate
analysis showed that a longer duration of hsPDA – not
Table 3 Multivariate analysis of variance (MANCOVA) of forced maximal flow (V’maxFRC), respiratory compliance (Crs), and airway
resistance (Raw) with patient characteristics as covariates
V’maxFRC Respiratory compliance Airway resistance
Source F ratio P value F ratio P value F ratio P value
Covariates
Gestational age <0.01 0.945 0.19 0.667 0.02 0.885
Birth weight 4.99 0.028 2.98 0.087 <0.01 0.991
Postconceptional age 4.22 0.043 7.69 0.007 0.37 0.544
Body weight 2.44 0.122 6.48 0.012 1.11 0.295
Duration hsPDA 0.26 0.609 0.05 0.821 0.65 0.423
Duration mechanical ventilation 0.43 0.513 2.29 0.133 0.08 0.773
Main effect
PDA ligation 2.73 0.102 1.68 0.198 22.00 <0.001
F ratios are based on the residual mean square error and p-values indicate the statistical significance of each factor
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surgery itself – was an independent risk factor for BPD.
In addition, there are contradictory results on the effects
of pharmacological PDA treatment on BPD rates [29].
Furthermore, hsPDA and its treatment influences pa-
rameters that affect pulmonary outcome, but cannot be
assessed by LFT, such as the pulmonary vasculature.
Prospective trials that include a non-treatment arm are
needed to address these issues.
Conclusions
In conclusion, despite the retrospective nature of our ana-
lysis and the aforementioned differences between the two
groups, we provide the first large cohort descriptive data
on postnatal LFT results in patients treated for hsPDA
using a panel of various techniques that were performed
by a single experienced investigator. We suggest that LFT
after discharge might help identify infants with increased
risk for upper airway obstructions. Despite the potential
harms, ligation provides definite PDA closure in infants
after failed pharmacological treatment. Nonetheless, the
optimal indication and time point for treatment are yet to
be determined, and a careful follow-up of this high-risk
population is mandatory in order to identify respiratory
and other sequelae after PDA ligation.
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